Medtronic plc Conference Call Summary Company Overview - **Company**: Medtronic plc (NYSE: MDT) - **Event**: 40th Annual J.P. Morgan Healthcare Conference - **Date**: January 10, 2022 Key Points Industry and Company Transformation - Medtronic is undergoing a significant transformation aimed at accelerating growth and improving competitiveness, initiated 18 months ago [5][36] - The company has restructured into 20 operating units, enhancing focus and decision-making, resulting in over 70% of units now holding or winning market share, up from 35% [5][22] Financial Performance and Market Position - Medtronic has achieved over 180 product approvals in the last 12 months and continues to invest heavily in R&D and M&A [7][26] - The company expects to maintain a long-term growth profile of over 5% top-line growth and over 8% bottom-line growth [50][53] Pipeline and Product Development - Key pipeline updates include: - **Symplicity Renal Denervation**: Delays in trials but expected to tap into a multibillion-dollar market opportunity [10] - **Hugo Robotic-Assisted Surgery System**: Adjusted revenue expectations due to supply chain issues, but high customer interest remains [11] - **Diabetes Products**: Facing regulatory challenges but ongoing remediation efforts are in place [12] - The company is optimistic about its robust pipeline, which is not reliant on a few products [28] Operational Challenges and Responses - The pandemic has impacted operations, with 14 out of 20 businesses reaching pre-COVID revenue levels, but staffing shortages remain a concern [13] - The strengthening U.S. dollar is expected to create currency headwinds, estimated at $30 million to $40 million for Q3 [14][15] Quality and Safety Initiatives - Medtronic is prioritizing patient safety and quality improvements following several recalls, with a focus on enhancing operational excellence [24][48] - A new capital allocation framework is in place to better manage investments across its portfolio [25] Strategic Acquisitions - The acquisition of Affera is aimed at enhancing Medtronic's cardiac ablation portfolio, with a transaction value of nearly $1 billion [30] - The company is also focusing on strategic customer relationships to drive growth [19] ESG Commitment - Medtronic is committed to being a leader in ESG practices, focusing on innovation, patient safety, and diversity [35] Future Outlook - The company is confident in its ability to deliver double-digit total shareholder returns, driven by a strong product pipeline and market leadership across multiple segments [34][36] Additional Insights - The transformation includes cultural changes to foster a more competitive environment, with a focus on accountability and performance-based incentives [17][20] - Medtronic is leveraging technology development centers to enhance innovation and reduce costs across its business units [18] This summary encapsulates the key points discussed during the Medtronic conference call, highlighting the company's strategic direction, operational challenges, and future growth prospects.

Medtronic plc (NYSE:MDT) Q2 2022 Earnings Conference Call November 23, 2021 8:00 AM ET Company Participants Ryan Weispfenning - Vice President & Head of Investor Relations Geoffrey Martha - Chairman & Chief Executive Officer Karen Parkhill - Chief Financial Officer Sean Salmon - EVP & President of the Cardiovascular and Diabetes Operating Unit Bob White - EVP & President of Medical Surgical Portfolio Brett Wall - EVP & President of Neuroscience Portfolio Conference Call Participants Robbie Marcus - JPMorga ...

- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ® FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 30, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________ Commission File Number 001-36820 MEDTRONIC PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ® FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________ Commission File Number 001-36820 MEDTRONIC PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State of inc ...